Evidence map›Paper›PMID 32399584›Full record

ArticleEuropean radiology experimental2020

Monitoring treatment effects in lung cancer-bearing mice: clinical CT and clinical MRI compared to micro-CT.

Judith E Spiro, Miriam Rinneburger, Dennis M Hedderich, Mladen Jokic, Hans Christian Reinhardt, David Maintz, Moritz Palmowski, Thorsten Persigehl

Abstract read
In one paragraph

Article in European radiology experimental, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Deep Learning-Based Chest CT Image Features in Diagnosis of Lung Cancer.Computational and mathematical methods in medicine · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Judith E SpiroDepartment of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. judith.spiro@med.uni-muenchen.de.
Miriam RinneburgerDepartment of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Dennis M HedderichDepartment of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Mladen JokicCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, Joseph-Stelzmann-Str. 26, 50931, Cologne, Germany.
Hans Christian ReinhardtCologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, Joseph-Stelzmann-Str. 26, 50931, Cologne, Germany.
David MaintzDepartment of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Moritz PalmowskiInstitute of Experimental Molecular Imaging, University Aachen, Forckenbeckstr. 55, 52074, Aachen, Germany.
Thorsten PersigehlDepartment of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.

Funding

Else Kröner-Fresenius-Stiftung 2016-Kolleg-19
6 · The paper itself

Abstract

backgroundCompared to histology-based methods, imaging can reduce animal usage in preclinical studies. However, availability of dedicated scanners is limited. We evaluated clinical computed tomography (CT) and magnetic resonance imaging (MRI) in comparison to dedicated CT (micro-CT) for assessing therapy effects in lung cancer-bearing mice.

methodsAnimals received cisplatin (n = 10), sham (n = 12), or no treatment (n = 9). All were examined via micro-CT, CT, and MRI before and after treatment. Semiautomated tumour burden (TB) calculation was performed. The Bland-Altman, receiver operating characteristic (ROC), and Spearman statistics were used.

resultsAll modalities always allowed localising and measuring TB. At all modalities, mice treated with cisplatin showed a TB reduction (p ≤ 0.012) while sham-treated and untreated individuals presented tumour growth (p < 0.001). Mean relative difference (limits of agreement) between TB on micro-CT and clinical scanners was 24.7% (21.7-27.7%) for CT and 2.9% (-4.0-9.8%) for MRI. Relative TB changes before/after treatment were not different between micro-CT and CT (p = 0.074) or MRI (p = 0.241). Mice with cisplatin treatment were discriminated from those with sham or no treatment at all modalities (p ≤ 0.001). Using micro-CT as reference standard, ROC areas under the curves were 0.988-1.000 for CT and 0.946-0.957 for MRI. TB changes were highly correlated across modalities (r ≥ 0.900, p < 0.001).

conclusionsClinical CT and MRI are suitable for treatment response evaluation in lung cancer-bearing mice. When dedicated scanners are unavailable, they should be preferred to improve animal welfare.

Indexed as

Magnetic Resonance ImagingTomography, X-Ray ComputedX-Ray MicrotomographyAnimalsCisplatinLung NeoplasmsMiceProspective StudiesTumor BurdenCisplatinCisplatinLung neoplasmsMagnetic Resonance ImagingMiceX-ray microtomography

Identifiers

PMID32399584
PMCPMC7218036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.